Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Mycoplasma pneumoniae fusion antigen as well as preparation method and application thereof

A technology of Mycoplasma pneumoniae and fusion antigen, which is applied in the biological field, can solve the problems of strict preparation process requirements, uneven product quality, human infection, etc., and achieves the effects of broad market prospects, high sensitivity and strong specificity.

Active Publication Date: 2020-08-18
ZHUHAI LIVZON DIAGNOSTICS
View PDF7 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The preparation process of MP whole bacterial antigen has strict requirements, complex steps, often mixed with other proteins, high price, uneven product quality between batches, and the risk of infecting humans during production and use

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Mycoplasma pneumoniae fusion antigen as well as preparation method and application thereof
  • Mycoplasma pneumoniae fusion antigen as well as preparation method and application thereof
  • Mycoplasma pneumoniae fusion antigen as well as preparation method and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0067] Example 1: Synthesis of target gene encoding P1M / P30A antigen and construction of recombinant vector

[0068] 1. Use software such as ProtScale to analyze the entire amino acid sequence of Mycoplasma pneumoniae (FH strain) antigens P1 and P30, screen out the antigenic protein sequences P1M: residues 1341-1518 and P30A: residues 170-182, and connect them with short peptides.

[0069] Design PCR primers HP-P1M / P30A-P1M-for, the sequence is:

[0070] CATCACAGCAGCGGCTGGCTGGTTGGCCAG,

[0071] and HP-P1M / P30A-P1M-rev, the sequence is:

[0072] CGGAAAACCGGTACGCTGCAGGGTCTGCGGACCTTG, use the recombinant plasmid pET28a-P1F (P1 antigen fragment residues: 1181-1525) preserved in our laboratory as a template to amplify the P1M nucleic acid fragment; the PCR amplification reaction system is:

[0073]

[0074] The PCR amplification reaction conditions are:

[0075] Pre-denaturation: 98°C, 2min;

[0076] Deformation, annealing, elongation: 98°C, 10s; 60°C, 20s; 72°C, 25s; cycle ...

Embodiment 2

[0105] Example 2: Induced expression and purification of Mycoplasma pneumoniae fusion antigen (P1M / P30A antigen)

[0106] 1, the recombinant vector P1M / p30A-pET28a among the embodiment 1 is transformed into Escherichia coli E.coli Rosetta (DE3) competent cell, in the LB containing the kanamycin of 50 μ g / ml and the chloramphenicol of 50 μ g / ml Cultivate on a culture plate at 37°C for 14-16 hours; screen positive recombinant bacteria, pick a single colony and inoculate it into 5ml LB medium containing 50μg / ml kanamycin and 50μg / ml chloramphenicol, and culture overnight .

[0107] 2. Inoculate the bacterium solution of the above-mentioned overnight culture into the 750ml LB medium containing the kanamycin of 50 μg / ml and the chloramphenicol of 50 μg / ml by 1% (v / v) inoculation amount, 37 ℃, 250rpm, Cultivate to bacterial solution OD 600 1.0-1.3, and then induced with IPTG with a final concentration of 0.5mM-1.0mM at 25°C and 250rpm for 3-4h.

[0108] 3. Collect the 0.75L mediu...

Embodiment 3

[0122] Embodiment 3: the preparation of other several mycoplasma pneumoniae antigens

[0123] Our laboratory also prepared P1M antigen (P1 antigen fragment: residues 1341-1518) and P1C antigen (P1 antigen fragment: residues 1288-1518).

[0124] Our laboratory also prepared several other fusion antigens of Mycoplasma pneumoniae, including P1M / P30C antigen, P1C / P30C antigen and P1C / P30A antigen, using a method similar to that of Examples 1 and 2.

[0125] 1. Preparation of P1M antigen: Use software such as ProtScale to analyze the entire amino acid sequence of Mycoplasma pneumoniae (FH strain) antigen P1, and screen out the protein sequence P1M containing antigenicity: residues 1341-1518. After codon optimization for Escherichia coli, use the whole gene The recombinant plasmid pET28a-P1M expressing P1M antigen was obtained by synthetic method, and transformed into Escherichia coli E. coli Rosetta (DE3); the expression and purification of the target protein P1M were induced.

[...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides a mycoplasma pneumoniae fusion antigen as well as a preparation method and application thereof, and relates to the technical field of biology. The mycoplasma pneumoniae fusion antigen is a fusion protein containing a P1M antigen fragment and a P30A antigen fragment. The mycoplasma pneumoniae fusion antigen provided by the invention is verified by an immunoserological detection technology, and compared with an existing mycoplasma pneumoniae antigen, the mycoplasma pneumoniae fusion antigen is stronger in specificity, higher in sensitivity, easy to culture and purify, morebeneficial to industrial production and lower in cost. The mycoplasma pneumoniae fusion antigen is suitable for preparation of MP antibody detection products, can be processed into products in any form in the field of in-vitro immunodiagnosis, and has a wide market prospect.

Description

technical field [0001] The invention relates to the field of biotechnology, in particular to a mycoplasma pneumoniae fusion antigen and its preparation method and application. Background technique [0002] Mycoplasma pneumoniae (MP) is a kind of pathogenic mycoplasma, which is an important pathogen of community-acquired pneumonia. Its infection can cause primary atypical pneumonia, and can also cause human respiratory infectious diseases such as bronchitis and pharyngitis. Cause complications involving the nervous system, blood system, cardiovascular system and skin, muscles, joints and so on. In conclusion, respiratory damage and various extrapulmonary complications caused by MP infection have attracted widespread attention. [0003] MP infection often has no specific clinical manifestations. Timely diagnosis of the etiology, prevention of disease progression, and early detection and early treatment have become the top priority for the treatment of MP infectious diseases. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07K19/00C12N15/70G01N33/569C12N15/62C12N1/21C12R1/19
CPCC07K14/30C07K2319/00G01N33/56933G01N2333/30G01N2469/20
Inventor 聂金梅何丽娟况承钰朱越谭胡志强陈巧红杨海林候宝凤
Owner ZHUHAI LIVZON DIAGNOSTICS
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com